By Fineline Cube 
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 biologic product SHR-4712 in advanced solid tumors. This marks a significant step forward in the development of novel therapeutic options for patients with advanced solid tumors.
SHR-4712 Mechanism and Innovation
SHR-4712 is designed to specifically bind to tumor-associated antigens and activate immune cells within the tumor microenvironment, thereby exerting targeted anti-tumor effects. There is currently no similar product approved globally, highlighting the potential of SHR-4712 to address significant unmet medical needs.
R&D Investment
Hengrui has invested RMB 24.92 million (USD 3.5 million) in the research and development of SHR-4712. This investment underscores the company’s commitment to innovation in oncology treatment.-Fineline Info & Tech